Study S000136

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

ClinicalTrials.gov record

Registration

Registration: NCT06534411
Acronym: REIMAGINE 5
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 1023
Start: 2024-11-05
Primary completion: 2026-06-02
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1300-2590; OTHER:2023-509600-15; NIH:2023

Registered primary outcomes

Change in Glycated Haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 60)]
Relative Change in Body Weight [From baseline (week 0) to end of treatment (week 60)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.